Post

Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort

New Phase IIb data suggests a combination therapy of Akero Therapeutics’s efruxifermin and Novo Nordisk’s Ozempic (semaglutide) can reduce liver …

ASCO 2023: Janssen present positive follow-up data for first in line therapy for lung cancer

Janssen Pharmaceuticals has presented long-term results from its CHRYSALIS study, which showed the combination of Rybrevant (amivantamab-vmjw) and lazertinib, was …

ASCO 2020: Janssen reports positive results for Talquetamab in Multiple myeloma

Johnson & Johnson (J&J) has reported results from its Phase I studies investigating talquetamab as a monotherapy and in combination …

ASCO 2023: Research backs chemo-only approach for some rectal cancer patients

Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …

Servier’s Phase III INDIGO trial of vorasidenib meets endpoints

Servier has reported that the Phase III INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 isocitrate …